Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase

International Journal of Cancer

Volumn 106, Issue 1, 2003, Pages 1-7

  Ellies, Lesley G ^a,c   Fishman, Michael ^a   Hardison, Joy ^a   Kleeman, Jeanine ^a   Maglione, Jeannie E ^a   Manner, Cathyryne K ^a   Cardiff, Robert D ^b   MacLeod, Carol L ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast; Cancer; iNOS; Mouse; Polyomavirus middle T antigen

Indexed keywords

CD31 ANTIGEN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RNA; VIRUS MIDDLE T ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; BREAST HYPERPLASIA; CONTROLLED STUDY; FEMALE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MACROPHAGE; METASTASIS POTENTIAL; MICROVASCULATURE; MITOSIS; MOUSE; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD31; ANTIGENS, POLYOMAVIRUS TRANSFORMING; BLOTTING, WESTERN; FEMALE; HETEROZYGOTE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOSIS; NEOPLASM METASTASIS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSGENES;

EID: 0038207007     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11178     Document Type: Article

References (52)

1. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42.
2. MacMicking JD, Xie Q, Nathan C. Nitric oxide and macrophage function. Ann Rev Immunol 1997;15:323-50.
3. Grisham MB, Jourd'heuil D, Wink DA. Review article: chronic inflammation and reactive oxygen and nitrogen metabolism: implications in DNA damage and mutagenesis. Aliment Pharmacol Ther 2000;14(Suppl 1):3-9.
4. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol Gastrointest Liver Physiol 2001;281:G626-34.
5. Jadeski LC, Chakraborty C, Lala PK. Role of nitric oxide in tumour progression with special reference to a murine breast cancer model. Can J Physiol Pharmacol 2002;80:125-35.
6. Dueñas-Gonzalez A, Isales CM, del Mar Abad-Hernandez M, Gonzalez-Sarmiento R, Sangueza O, Rodriguez-Commes J. Expression of inducible nitric oxide synthase in breast cancer correlates with metastatic disease. Mod Pathol 1997;10:645-9.
7. Cendan JC, Topping DL, Pruitt J, Snowdy S, Copeland EM III, Lind DS. Inflammatory mediators stimulate arginine transport and arginine-derived nitric oxide production in a murine breast cancer cell line. J Surg Res 1996;60:284-8.
8. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
9. Vakkala M, Kahlos K, Lakari E, Paakko P, Kinnula V, Soini Y. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 2000;6:2408-16.
10. Phoa N, Epe B. Influence of nitric oxide on the generation and repair of oxidative DNA damage in mammalian cells. Carcinogenesis 2002; 23:469-75.
11. Jadeski LC, Lala PK. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors. Am J Pathol 1999;155:1381-90.
12. Jadeski LC, Hum KO, Chakraborty C, Lala PK. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 2000;86:30-9.
13. Tschugguel W, Schneeberger C, Unfried G, Czerwenka K, Weninger W, Mildner M. Gruber DM, Sator MO, Waldhor T, Huber JC. Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade. Breast Cancer Res Treat 1999;56:145-51.
14. Reveneau S, Arnould L, Jolimoy G, Hilpert S, Lejeune P, Saint-Giorgio V, Belichard C, Jeannin JF. Nitric oxide synthase in human breast cancer is associated with tumor grade, proliferation rate, and expression of progesterone receptors. Lab Invest 1999;79:1215-25.
15. Martin JH, Alalami O, van den Berg HW. Reduced expression of endothelial and inducible nitric oxide synthase in a human breast cancer cell line which has acquired estrogen independence. Cancer Lett 1999;144:65-74.
16. Bani D, Masini E, Bello MG, Bigazzi M, Sacchi TB. Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells. Cancer Res 1995;55:5272-5.
17. Binder C, Schulz M, Hiddemann W, Oellerich M. Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-alpha-induced apoptosis in MCF-7 and other epithelial tumor cells. Lab Invest 1999;79:1703-12.
18. Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 2001;61:1100-6.
19. Cardiff RD, Bern HA, Faulkin LJ, Daniel CW, Smith GH, Young LJ, Medina D, Gardner MB, Wellings SR, Shyamala G, Guzman RC, Rajkumar L, et al. Contributions of mouse biology to breast cancer research. Comp Med 2002;52:12-31.
20. Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R, Furth P, Hunter K, Kucherlapati R, Simon R, Liu ET, Green JE. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 2002;99:6967-72.
21. Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR, MacLeod CL, Shyamala G, Gillgrass AE, Cardiff RD. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 2002;161:1087-97.
22. Cardiff RD, Wellings SR. The comparative pathology of human and mouse mammary glands. J Mamm Gland Biol Neoplasia 1999;4:105-22.
23. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
24. Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ, Kelly P, Harris AL, Horne CH. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989;49: 2087-90.
25. Schondorf T, Andrack A, Niederacher D, Scharl A, Becker M, Engel H, Gohring UJ. H-ras gene amplification or mutation is not common in human primary breast cancer. Oncol Rep 1999;6:1029-33.
26. Guy C, Cardiff R, Muller W, Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol, 1992;12:954-61.
27. Laubach V, Shesely E, Smithies O, Sherman P. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA 1995;92:10688-92.
28. Elliott J, Jones MD, Griffin BE, Krauzewicz N. Regulation of cytoskeletal association by a basic amino acid motif in polyoma virus middle T antigen. Oncogene 1998:17:1797-806.
29. Nicholson B, Manner CK, Kleeman J, MacLeod CL. Sustained nitric oxide production in macrophages requires the arginine transporter CAT2. J Biol Chem 2001;276:15881-5.
30. Rappolee DA, Wang A, Mark D, Werb Z. Novel method for studying mRNA phenotypes in single or small numbers of cells. J Cell Biochem 1989;39:1-11.
31. Miller RG Jr, Simultaneous statistical inference. New York: Springer-Verlag, 1981.
32. Burnett TG, Tash JS, Hunt JS. Investigation of the role of nitric oxide synthase 2 in pregnancy using mutant mice. Reproduction 2002;124: 49-57.
33. Muller WJ, Neville MC. Introduction: signaling in mammary development and tumorigenesis. J Mamm Gland Biol Neoplasia 2001;6: 1-5.
34. Fu YX, Watson GA, Kasahara M, Lopez DM. The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma: I, induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. J Immunol 1991; 146:783-9.
35. Jaffe ML, Arai H, Nabel GJ. Mechanisms of tumor-induced immunosuppression: evidence for contact-dependent T cell suppression by monocytes. Mol Med 1996;2:692-701.
36. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 2002;168: 689-95.
37. Chiarugi V, Magnelli L, Gallo O. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis. Int J Mol Med 1998;2:715-9.
38. Sutherland RM, Rasey JS, Hill RP. Tumor biology. Am J Clin Oncol 1988;11:253-74.
39. Kim YM, Talanian RV, Li J, Billiar TR. Nitric oxide prevents IL-1beta and IFN-gamma-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1beta-converting enzyme). J Immunol 1998;161:4122-8.
40. Hochberg D, Johnson CW, Chen J, Cohen D, Stern J, Vaughan EDJ, Poppas D, Felsen D. Interstitial fibrosis of unilateral ureteral obstruction is exacerbated in kidneys of mice lacking the gene for inducible nitric oxide synthase. Lab Invest 2000;80:1721-8.
41. Le Voyer T, Lu Z, Babb J, Lifsted T, Williams M, Hunter K. An epistatic interaction controls the latency of a transgene-induced mammary tumor. Mamm Genome 2000;11:883-9.
42. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000;19:968-88.
43. Kisley LR, Barrett BS, Bauer AK, Dwyer-Nield LD, Barthel B, Meyer AM, Thompson DC, Malkinson AM. Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res 2002:62:6850-6.
44. De Paepe B, Verstraeten VM, De Potter CR, Bullock GR. Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem Cell Biol 2002;117:13-9.
45. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
46. Konopka TE, Barker JE, Bamford TL, Guida E, Anderson RL, Stewart AG. Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production. Cancer Res 2001;61:3182-7.
47. Maglione J, Moghanaki D, Young LJ, Manner CK, Ellies LG, Joseph S, Nicholson B, Cardiff RD, MacLeod CL. Transgenic polyoma middle-T mice model premalignant mammary disease. Cancer Res 2001;61:8298-305.
48. Stanley ER, Guilbert LJ, Tushinski RJ, Bartelmez SH. CSF-1: a mononuclear phagocyte lineage-specific hemopoietic growth factor. J Cell Biochem 1983;21:151-9.
49. Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med 1995;27:79-85.
50. Scholl SM, Pallud C, Beuvon F, Hacene K, Stanley ER, Rohrschneider L, Tang R, Pouillart P, Lidereau R. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 1994;86:120-6.
51. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:727-40.
52. Gerling IC, Karlsen AE, Chapman HD, Andersen HU, Boel E, Cunningham JM, Nerup J, Leiter EH. The inducible nitric oxide synthase gene, Nos2, maps to mouse chromosome 11. Mamm Genome 1994; 5:318-20.